Latest filing published 13 Feb 2026 for LABCORP HOLDINGS INC.. Read the official filing
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Garheng Kong (board member) discloses dealings in 4 companies, chiefly Xeris Biopharma Holdings, Inc., Labcorp Holdings Inc. and Strongbridge Biopharma plc. We count 17 filings; the first trade dates from 14 May 2021 and the latest from 11 February 2026.
The open-market record is one-sided, with 1 purchase and not one sale. No amount is published for 1 filing, which the totals therefore leave out. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 9 share grants and 5 option exercises.
The record was last updated on 13 February 2026 with an option exercise in Labcorp Holdings Inc. The latest purchase dates back some time: it was published 1,766 days ago, on 17 December 2021. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
17 of 17 declarations